NASDAQ:CTNM

Contineum Therapeutics Q3 2026 Earnings Results & Report

Contineum Therapeutics logo
$8.67 -0.37 (-4.12%)
As of 03:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Contineum Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 3, 2026. The company reported EPS of -$0.49 versus the -$0.4538 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
After Market Closes
Conference Call
4:00 PM ET

Contineum Therapeutics EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.4538
Beat/Miss
Missed by -$0.0363
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Contineum Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
$5.65 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Contineum Therapeutics Q3 2026 Earnings FAQ

Contineum Therapeutics (NASDAQ:CTNM) reported earnings of -$0.49 per share for Q3 2026, missing the consensus estimate of -$0.4538. The report was announced on Tuesday, November 3, 2026.

Contineum Therapeutics Earnings Headlines

ELON + YOU + DECEMBER 8TH
Elon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th. A free Masterclass claims to reveal what Musk filed with regulators and why he's working to keep it quiet.tc pixel
See More Contineum Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Contineum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Contineum Therapeutics and other key companies, straight to your email.

About Contineum Therapeutics

Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for neurological, inflammatory and fibrotic diseases. The company is based in San Diego, California, and was previously known as Pipeline Therapeutics.

Its development programs include PIPE-307, an investigational M1 receptor antagonist being studied for neurological conditions, including relapsing-remitting multiple sclerosis. Contineum is also developing PIPE-791, an investigational LPA1 receptor antagonist for fibrotic lung diseases and related conditions.

Contineum’s programs are in clinical development, and the company does not currently offer approved medicines for sale. Its work centers on advancing potential therapies through clinical testing for conditions with significant unmet medical needs.

View Contineum Therapeutics Profile